Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 190

1.

Androgen receptor status is a prognostic marker in non-basal triple negative breast cancers and determines novel therapeutic options.

Gasparini P, Fassan M, Cascione L, Guler G, Balci S, Irkkan C, Paisie C, Lovat F, Morrison C, Zhang J, Scarpa A, Croce CM, Shapiro CL, Huebner K.

PLoS One. 2014 Feb 5;9(2):e88525. doi: 10.1371/journal.pone.0088525. eCollection 2014.

2.

Loss of androgen receptor expression predicts early recurrence in triple-negative and basal-like breast cancer.

Thike AA, Yong-Zheng Chong L, Cheok PY, Li HH, Wai-Cheong Yip G, Huat Bay B, Tse GM, Iqbal J, Tan PH.

Mod Pathol. 2014 Mar;27(3):352-60. doi: 10.1038/modpathol.2013.145. Epub 2013 Aug 9.

3.

L1CAM is expressed in triple-negative breast cancers and is inversely correlated with androgen receptor.

Doberstein K, Milde-Langosch K, Bretz NP, Schirmer U, Harari A, Witzel I, Ben-Arie A, Hubalek M, Müller-Holzner E, Reinold S, Zeimet AG, Altevogt P, Fogel M.

BMC Cancer. 2014 Dec 15;14:958. doi: 10.1186/1471-2407-14-958.

4.

Gene-expression molecular subtyping of triple-negative breast cancer tumours: importance of immune response.

Jézéquel P, Loussouarn D, Guérin-Charbonnel C, Campion L, Vanier A, Gouraud W, Lasla H, Guette C, Valo I, Verrièle V, Campone M.

Breast Cancer Res. 2015 Mar 20;17:43. doi: 10.1186/s13058-015-0550-y.

5.

Prognostic markers in triple-negative breast cancer.

Rakha EA, El-Sayed ME, Green AR, Lee AH, Robertson JF, Ellis IO.

Cancer. 2007 Jan 1;109(1):25-32.

6.

Decreased expression of key tumour suppressor microRNAs is associated with lymph node metastases in triple negative breast cancer.

Avery-Kiejda KA, Braye SG, Mathe A, Forbes JF, Scott RJ.

BMC Cancer. 2014 Jan 31;14:51. doi: 10.1186/1471-2407-14-51.

7.

Comparison of basal-like triple-negative breast cancer defined by morphology, immunohistochemistry and transcriptional profiles.

Gazinska P, Grigoriadis A, Brown JP, Millis RR, Mera A, Gillett CE, Holmberg LH, Tutt AN, Pinder SE.

Mod Pathol. 2013 Jul;26(7):955-66. doi: 10.1038/modpathol.2012.244. Epub 2013 Feb 8.

8.

Identification and prognostic value of anterior gradient protein 2 expression in breast cancer based on tissue microarray.

Guo J, Gong G, Zhang B.

Tumour Biol. 2017 Jul;39(7):1010428317713392. doi: 10.1177/1010428317713392.

PMID:
28671019
9.

Potential prognostic tumor biomarkers in triple-negative breast carcinoma.

Peng Y.

Beijing Da Xue Xue Bao. 2012 Oct 18;44(5):666-72. Review.

10.

Histological Features and Tissue Microarray Taxonomy of Nigerian Breast Cancer Reveal Predominance of the High-Grade Triple-Negative Phenotype.

Titloye NA, Foster A, Omoniyi-Esan GO, Komolafe AO, Daramola AO, Adeoye OA, Adisa AO, Manoharan A, Pathak D, D'Cruz MN, Alizadeh Y, Lewis PD, Shaaban AM.

Pathobiology. 2016;83(1):24-32. doi: 10.1159/000441949. Epub 2016 Jan 6.

PMID:
26730581
11.

Androgen receptor status is highly conserved during tumor progression of breast cancer.

Grogg A, Trippel M, Pfaltz K, Lädrach C, Droeser RA, Cihoric N, Salhia B, Zweifel M, Tapia C.

BMC Cancer. 2015 Nov 9;15:872. doi: 10.1186/s12885-015-1897-2.

12.

Differential expression of epithelial–mesenchymal transition and stem cell markers in intrinsic subtypes of breast cancer.

Pomp V, Leo C, Mauracher A, Korol D, Guo W, Varga Z.

Breast Cancer Res Treat. 2015 Nov;154(1):45-55.

PMID:
26467042
13.

Dysregulation of the epigenome in triple-negative breast cancers: basal-like and claudin-low breast cancers express aberrant DNA hypermethylation.

Roll JD, Rivenbark AG, Sandhu R, Parker JS, Jones WD, Carey LA, Livasy CA, Coleman WB.

Exp Mol Pathol. 2013 Dec;95(3):276-87. doi: 10.1016/j.yexmp.2013.09.001. Epub 2013 Sep 14.

PMID:
24045095
14.

Hypermethylation of BRCA1 gene: implication for prognostic biomarker and therapeutic target in sporadic primary triple-negative breast cancer.

Zhu X, Shan L, Wang F, Wang J, Wang F, Shen G, Liu X, Wang B, Yuan Y, Ying J, Yang H.

Breast Cancer Res Treat. 2015 Apr;150(3):479-86. doi: 10.1007/s10549-015-3338-y. Epub 2015 Mar 18.

PMID:
25783183
15.

Expression of p53 protein product in triple negative breast cancers and relation with clinical and histopathological parameters.

Jasar D, Smichkoska S, Kubelka K, Filipovski V, Petrushevska G.

Pril (Makedon Akad Nauk Umet Odd Med Nauki). 2015;36(1):69-79.

PMID:
26076776
16.

Comparison of molecular subtype distribution in triple-negative inflammatory and non-inflammatory breast cancers.

Masuda H, Baggerly KA, Wang Y, Iwamoto T, Brewer T, Pusztai L, Kai K, Kogawa T, Finetti P, Birnbaum D, Dirix L, Woodward WA, Reuben JM, Krishnamurthy S, Symmans W, Van Laere SJ, Bertucci F, Hortobagyi GN, Ueno NT.

Breast Cancer Res. 2013 Nov 25;15(6):R112. doi: 10.1186/bcr3579.

17.

Novel genes associated with lymph node metastasis in triple negative breast cancer.

Mathe A, Wong-Brown M, Morten B, Forbes JF, Braye SG, Avery-Kiejda KA, Scott RJ.

Sci Rep. 2015 Nov 5;5:15832. doi: 10.1038/srep15832.

18.

Association of increased osteopontin and splice variant-c mRNA expression with HER2 and triple-negative/basal-like breast carcinomas subtypes and recurrence.

Ortiz-Martínez F, Perez-Balaguer A, Ciprián D, Andrés L, Ponce J, Adrover E, Sánchez-Payá J, Aranda FI, Lerma E, Peiró G.

Hum Pathol. 2014 Mar;45(3):504-12. doi: 10.1016/j.humpath.2013.10.015. Epub 2013 Oct 30.

PMID:
24440093
19.

Prognostic value of survivin and EGFR protein expression in triple-negative breast cancer (TNBC) patients.

Zhang M, Zhang X, Zhao S, Wang Y, Di W, Zhao G, Yang M, Zhang Q.

Target Oncol. 2014 Dec;9(4):349-57.

PMID:
24233638
20.

Expression and clinical significance of androgen receptor in triple negative breast cancer.

Luo X, Shi YX, Li ZM, Jiang WQ.

Chin J Cancer. 2010 Jun;29(6):585-90.

Supplemental Content

Support Center